糖皮质激素对类风湿关节炎骨质疏松影响的系统综述与荟萃分析
该系统综述与荟萃分析纳入15项观察性研究,评估糖皮质激素对类风湿关节炎(RA)患者骨密度及骨质疏松和骨折患病率的影响。结果显示,接受糖皮质激素治疗的RA患者腰椎和股骨颈骨密度显著低于RA对照及健康对照,骨质疏松和椎体骨折常见。提示使用糖皮质激素治疗RA时应采取策略预防骨质量下降。
要点
- 糖皮质激素治疗RA患者腰椎和股骨颈骨密度显著低于RA对照。
- 与健康对照相比,糖皮质激素治疗RA患者骨密度下降更明显。
- RA患者全身、脊柱、股骨骨质疏松患病率分别为38.6%、32.9%、21.7%,椎体骨折患病率13.0%。
核心结论
- 糖皮质激素可能对RA患者的骨骼健康产生负面影响,尤其椎体和股骨骨密度下降,骨质疏松和骨折常见。
- 使用糖皮质激素治疗RA时,应采取策略性措施预防骨质量下降。
研究设计与样本
- 系统综述与荟萃分析,检索EMBASE、Web of Science、PubMed和Cochrane Library至2019年6月26日。
- 纳入15项观察性研究,包括46,711例RA受试者和857例健康对照。
- 使用Stata 15进行荟萃分析并计算95%CI。
主要发现
- 糖皮质激素治疗的RA患者腰椎骨密度较RA对照低-0.038 g/cm2(95%CI -0.052至-0.024),股骨颈低-0.017 g/cm2(95%CI -0.030至-0.003)。
- 与健康对照相比,糖皮质激素治疗的RA患者腰椎骨密度低-0.094 g/cm2(95%CI -0.126至-0.061),股骨颈低-0.097 g/cm2(95%CI -0.109至-0.085)。
- 全身骨质疏松患病率38.6%(95%CI 0.305-0.466),脊柱32.9%(95%CI 0.277-0.381),股骨21.7%(95%CI 0.106-0.328),椎体骨折患病率13.0%(95%CI 0.058-0.203)。
临床怎么用
- 临床使用糖皮质激素治疗RA时,应关注骨密度变化并采取策略预防骨质量下降。
- 对RA患者,尤其使用糖皮质激素者,需评估骨质疏松和骨折风险。
- 治疗措施应个体化,但具体方案需进一步研究。
局限性
- 纳入研究均为观察性研究。
- 治疗措施需进一步研究以明确个体化方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We evaluated the effects of glucocorticoids on bone mineral density (BMD), and prevalence of osteoporosis and fracture in rheumatoid arthritis (RA) by meta-analysis. Until June 26, 2019, we conducted a systematic literature search in EMBASE, Web of science, PubMed, and Cochrane Library to obtain BMD and the prevalence of osteoporosis and fracture in glucocorticoid-treated subjects with RA. The BMD of the treatment and control groups were analyzed by meta-analysis (Stata. version 15), and the 95% confidence interval (CI) was calculated. We identified 15 observational studies, including 46,711 RA subjects and 857 healthy controls. The BMD of the lumbar spine (- 0.038 g/cm2; CI, - 0.052, - 0.024) and femoral neck (- 0.017 g/cm2; - 0.030, - 0.003) in RA treated with glucocorticoids were significantly lower than those in RA controls. Compared with healthy control group, the BMD of the lumbar spine (- 0.094 g/cm2; - 0.126, - 0.061) and femoral neck (- 0.097 g/cm2, - 0.109, - 0.085) of RA treated with glucocorticoids decreased more significantly. The prevalence of osteoporosis in whole body, spine, and femur was 38.6% (0.305, 0.466), 32.9% (0.277, 0.381), and 21.7% (0.106, 0.328), respectively. And the prevalence of vertebral fracture was 13.0% (0.058, 0.203). Glucocorticoids may lead to a decline in skeletal health in subjects with RA, especially in vertebral and femoral BMD, compared with normal people or RA without glucocorticoid therapy. Meanwhile, osteoporosis and fractures were also common. Therapeutic measures should be targeted at individuals, which needs further study. Through meta-analysis, we found that glucocorticoids have some negative effects on the bone health of subjects with rheumatoid arthritis. Therefore, when using glucocorticoids to treat rheumatoid arthritis, we should take strategic measures to prevent the decline of bone quality.
引用
- Wang Y, Zhao R, Gu Z, et al. Effects of glucocorticoids on osteoporosis in rheumatoid arthritis: a systematic review and meta-analysis. Osteoporos Int. 2020. PMID: 32291467. doi:10.1007/s00198-020-05360-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。